Монурал

Quick links to important sections

Монурал

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Монурал

Property Description
Active Ingredient Fosfomycin trometamol
Form Granules for Oral Solution (Powder in Sachet)
Pharmacological Class Antibiotic / Broad-spectrum Antibacterial Agent
Common Use Domain Elimination of susceptible bacterial pathogens (Anti-infective)
Origin Synthetic (Phosphonic acid derivative)

What Type of Medicine is Монурал?

Монурал is a prescription pharmaceutical product classified as a unique, broad-spectrum antibiotic and antibacterial agent. It is the primary trade name for a preparation containing the active ingredient Fosfomycin, specifically utilized as the salt Fosfomycin trometamol. Its distinct pharmacological classification, which is clinically recognized for its role in anti-infective therapy, places it in a category separate from widely known groups like beta-lactam antibiotics.

As a phosphonic acid derivative, Fosfomycin possesses a chemical structure that differs significantly from most older antibiotics. This difference is key because it minimizes the risk of established cross-resistance with other major drug classes, preserving its effectiveness against a specific range of susceptible microbial pathogens. The active ingredient, Fosfomycin, is entirely synthetic in origin, developed specifically for its targeted anti-infective properties.

Composition, Origin, and Dosage Form

The core therapeutic component is Fosfomycin trometamol, which is supplied in the specialized form of granules for oral solution. These granules are typically packaged in a single-dose sachet, a convenient format designed to simplify the preparation before consumption and facilitate simple oral administration. The brand Монурал is often associated with this single-administration model, a practical differentiation in anti-infective delivery.

The trometamol salt acts as a pro-drug designed to significantly enhance the drug's absorption and bioavailability following ingestion. This single-ingredient product is engineered to deliver a high concentration of the active Fosfomycin component to the necessary site.

General Therapeutic Purpose of Fosfomycin

The general purpose of Fosfomycin is to achieve potent bactericidal action to eliminate the bacteria responsible for acute infections. It operates by interfering with the microbial building process at its earliest stage, targeting the vital enzymes required for the bacteria to construct their protective cell wall. This unique, early-stage intervention is characterized by its rapid effect on susceptible pathogens. This mechanism serves the broad therapeutic purpose of swiftly resolving bacterial infections by neutralizing the causative pathogens and preventing their proliferation.

What side effects are possible with Монурал?

Possible Side Effects and Safety Information

The safety profile of Fosfomycin trometamol is officially defined by specific classifications of adverse reactions and mandated usage constraints documented in regulatory labeling.

Frequency-Classified Adverse Reactions

Adverse events are categorized according to regulatory frequency standards. Common reactions (occurring in 1 to 10 out of 100 patients) generally involve gastrointestinal and nervous system disturbances, including diarrhoea, nausea, headache, and dizziness. Vulvovaginitis is also classified as common. Less frequent, Uncommon events include vomiting, rash, and pruritus (itching).

Serious Adverse Reactions and Key Constraints

Official labeling documents serious, clinically significant risks. These include the potential for severe, occasionally fatal hypersensitivity reactions, such as anaphylaxis and angioedema, which have a Not Known frequency. There is also a documented risk of severe gastrointestinal complications, such as Antibiotic-associated colitis (C. difficile-associated diarrhea), which can be life-threatening.

Safety limitations include a contraindication for individuals with known hypersensitivity to the drug or any of its ingredients. The product's safety and efficacy are not established for use in children below 12 years of age.

Population-Specific Safety Notes

The regulatory documents note that Fosfomycin crosses the placenta and is excreted in breast milk; therefore, use during pregnancy and breast-feeding is permitted only if clearly necessary. Caution is advised when the medicine is used in older adults due to the increased possibility of age-related renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding overdose of Монурал (fosfomycin trometamol) details specific clinical manifestations and mandates immediate emergency action. Experience with oral overdose is limited, but reported signs must be addressed promptly.


Documented Overdose Presentations

An overdose may be associated with specific sensory and neurological changes, including impaired hearing, vestibular loss (loss of balance), and changes in taste perception, such as a metallic taste. In higher exposure or intravenous contexts, hypotonia (decreased muscle tone) and somnolence (drowsiness) have also been reported. Severe outcomes noted in high-exposure cases include electrolyte disturbances, thrombocytopenia, and hypoprothrombinemia.


Required Emergency Actions

The regulatory guidance mandates seeking immediate medical attention upon any suspected overdose. Emergency services should be contacted if the affected individual has collapsed, had a seizure, or is experiencing trouble breathing or inability to be awakened.


Overdose Management

No specific antidote is known for fosfomycin overdose, meaning treatment is strictly symptomatic and supportive. Supportive measures include rehydration to assist in the elimination of the active substance. Patient monitoring is required, with specific attention given to plasma/serum electrolyte levels.

Therapeutic Uses of Монурал

What Монурал Treats: Main Uses and Benefits

This medication is commonly used to help manage acute symptoms associated with a lower urinary tract infection, such as cystitis (bladder infection), and is relevant in areas where short-term symptom management is appropriate. Specifically, it is applied in addressing conditions presenting with symptoms related to physical discomfort of urination (dysuria), and is used when groups of symptoms, like urinary frequency and urgency, interfere with daily comfort. The oral granules are commonly used for acute, uncomplicated cystitis, and are also considered relevant for preventing infection in specific procedural contexts.

Symptomatic Benefit

It contributes to improved comfort during periods of heightened symptoms, supporting patients during difficult episodes by easing distress. It is used in areas where short-term symptom management is appropriate, assisting with maintaining functional stability.

Quick Fact: Managing Acute Bladder Discomfort Symptoms

Clinical Scenarios

Commonly used across conditions presenting with acute episodes, the medication is applied during phases when symptoms become more noticeable. This includes sudden onset of painful urination and the need for frequent restroom visits, as well as for preventing infection for procedures that may cause temporary functional strain.

Eligibility and Restrictions for Use

Монурал (Fosfomycin trometamol) eligibility is defined by strict regulatory criteria focused on patient population, age, and organ function. The regulatory profile establishes absolute prohibitions and conditional use rules.

Contraindications and Absolute Restrictions

Монурал must not be used by patients with a documented history of hypersensitivity to fosfomycin trometamol or any of the formulation's components. Use is formally contraindicated in individuals with severe renal impairment or those undergoing hemodialysis, as kidney function significantly affects drug excretion.

Age-Related Eligibility

The medicine is primarily established for use in adult women 18 years of age and older for the treatment of uncomplicated urinary tract infections. Use in children under 12 years of age is officially not established in the US, and it is not recommended for acute cystitis in the EU. Older adult patients may use the medicine but require caution due to the higher probability of decreased renal function.

Conditional Use and Special Populations

Use is conditional in women who are pregnant, permitted only if clearly needed when potential benefit justifies the risk. For lactating women, official guidance requires a decision to either discontinue nursing or discontinue the medication due to drug excretion into breast milk. The medicine is restricted to treating only uncomplicated lower urinary tract infections.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Fosfomycin trometamol (Монурал) is primarily defined by documented pharmacokinetic interactions that alter the drug's exposure, rather than classical metabolic enzyme interactions.

Documented Drug and Substance Interactions

Interacting Substance Official Interaction Outcome (Regulatory Description)
Metoclopramide Lowers the serum concentrations and urinary excretion of fosfomycin. This pharmacokinetic interaction may result in reduced drug exposure.
Drugs that increase gastrointestinal motility May produce a similar effect to Metoclopramide, lowering systemic fosfomycin levels.
Food (Meals) Reduces the oral bioavailability of fosfomycin. A high-fat meal specifically lowers the maximum serum concentration (Cmax).
Cimetidine Does not affect the pharmacokinetics of fosfomycin when coadministered, a non-interaction noted in official documentation.

Administration-Timing and Population Constraints

The reduction in bioavailability caused by food necessitates a specific timing constraint: the medicine must be administered while fasting or separated by 2 to 3 hours from meals.

Additionally, the regulatory profile includes a population-specific interaction note: Renal impairment significantly decreases the excretion of fosfomycin, leading to an increased elimination half-life and altered systemic exposure.

Mechanism of Action

Irreversible Covalent Inhibition of Bacterial Cell Wall Precursor Enzyme

This mechanistic domain centers on Fosfomycin's direct and permanent attack on the foundational bacterial enzyme UDP-N-acetylglucosamine enolpyruvyl transferase ( MurA). By forming an irreversible covalent bond, the drug halts the synthesis of the essential peptidoglycan precursor ( UDP-MurNAc) at the very first step of construction, consequently compromising the pathogen's structural integrity.


Mechanistic Cascade: From Enzyme Blockade to Cell Lysis

The blockade of precursor formation initiates a rapid cascade where the bacterial cell develops a defective cell wall. Unable to withstand its internal osmotic pressure, the cell swells and ruptures, leading to cell lysis and death. This sequence defines the drug's mechanism as intrinsically bactericidal against susceptible pathogens.


️ Active Transport Mechanisms for Intracellular Entry

A crucial step in the mechanism is the drug's entry into the bacterial cytoplasm, facilitated by its resemblance to natural nutrients. Fosfomycin is actively transported into the cell using the pathogen's own Glycerol-3-phosphate ( GlpT) and Hexose-6-phosphate ( UhpT) systems, mediating the accumulation of a high concentration of the molecule at the intracellular target ( MurA). This specialized transport mechanism is essential for the molecule to reach its site of action.

Dosage and Administration Information

Official Administration Protocol

Монурал's administration is governed by a precise protocol designed to ensure optimal delivery of the active ingredient, fosfomycin trometamol. The pharmaceutical product is provided exclusively as granules for oral solution and is intended for consumption via the oral route. The standard dose for acute, uncomplicated conditions is a single 3 g administration. A different regimen involving two 3 g doses is employed for surgical prophylaxis, where the first dose is taken pre-procedure, and the second is taken 24 hours later.

Preparation and Timing Requirements

To prepare the medication, the entire contents of the sachet must be fully dissolved in a glass of water and consumed immediately upon mixing; the product must never be ingested in its dry, granular form. Administration is recommended on an empty stomach—separated from meals by two to three hours—and is often scheduled before bedtime after the patient has emptied their bladder. Since the core regimen for this indication is a single dose, no instructions regarding missed doses are applicable.

Population and Contextual Rules

Standard guidelines apply to specific populations. The 3 g oral dose is utilized for female adolescents over 12 years of age. No dosage adjustment is typically required for older adults. A key administration constraint is the need to avoid co-administration with metoclopramide or similar gastrointestinal motility agents, as this combination can reduce the drug's effectiveness.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Монурал (Fosfomycin)

Research Evidence for Acute, Uncomplicated Cystitis (AUC)

Research examined the use of Monural (Fosfomycin) in women experiencing acute, uncomplicated cystitis, which are conditions involving periods of heightened symptoms related to the lower urinary tract. Studies conducted for this purpose primarily include Randomized Controlled Trials (RCTs) and several Systematic Reviews. These studies were applied in research exploring how symptoms change over time and how the populations studied reported their experience. Studies monitored outcomes related to physical discomfort and the microbiological clearance of the bacteria. Findings describe patterns observed in these studies where the outcomes measured in the Monural groups were similar to the outcomes reported for groups treated with other antibiotics commonly used for this type of condition. While the certainty for short-term microbiological clearance appears relatively high in regulatory-referenced reviews, long-term effects are not fully established. Follow-up durations were limited, often tracking patients for only up to 30 days post-treatment.

Research Evidence for Prophylaxis in Specific Medical Procedures

Monural was studied for use in a specific preventative context, used to explore whether it contributes to avoidance of infectious complications following transrectal prostate biopsy in men. The evidence base here consists mainly of Systematic Reviews and various Non-Randomized Comparative Studies. Research examined whether a single dose could be observed in studies, and studies monitored outcomes related to the prevention of post-procedural infectious complications. Findings indicate that in these specific procedural contexts, studies reported patterns of post-procedural complication rates that differed from those measured in control groups. However, evidence quality varies across studies, with many findings derived from protocols involving multiple administrations of the oral preparation.

Evidence in Pediatric and Other Special Populations

The evidence landscape for use in children (pediatric populations) is limited. Research examined outcomes in children under 12, but sample sizes were modest and the studies monitored were not sufficiently large or numerous to clearly describe the outcomes observed in children. Research describes that the outcomes observed in pediatric studies were inconsistent or insufficient to establish a clear profile. Furthermore, the comparative evidence is lacking against the newest alternative antibiotics, as many foundational studies were conducted using older comparators.

Key Studies & References

  1. Fosfomycin trometamol for the treatment of urinary tract infections in pregnant women: an updated review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Монурал (FAQ)

Q: Is Монурал used for infections other than UTIs?

Official information states that the oral form is generally indicated for the treatment of uncomplicated urinary tract infections (UTIs) in women. Regulatory documents also authorize its use for the prevention of infection in men who are undergoing a transrectal prostate biopsy procedure.


Q: What is the usual duration of action for a single dose of Монурал?

According to official pharmacokinetic data, the mean elimination half-life of the active ingredient, fosfomycin, following a single oral dose is approximately 5.7 hours.


Q: How quickly does Монурал start to work after taking it?

The drug achieves high concentrations in the urine quickly after administration. However, clinical drug guide information indicates that the actual improvement in infection symptoms may take between 24 to 48 hours to become noticeable.


Q: Is it normal to feel a change in symptoms immediately after taking Монурал?

Since symptom improvement is generally reported to begin within 24 to 48 hours, it is generally not expected to feel a change immediately after taking the dose. The drug works quickly to reach high concentrations in the urine, but clinical relief takes time.


Q: Why is Монурал often prescribed as a single dose?

The single-dose regimen is supported by the drug’s ability to provide a high concentration of the active ingredient that is sustained in the urine, which is the site of the infection. This sustained presence supports its potent action against susceptible pathogens.


Q: Does Монурал interact with common pain relievers?

Official information advises caution, as certain common over-the-counter pain relievers, such as acetaminophen and some NSAIDs, may affect the rate at which fosfomycin is eliminated from the body. Patients should be cautious, as this may affect how the body processes the drug.


Q: Are there specific foods or drinks that should be avoided when taking Монурал?

To support proper absorption, regulatory instructions advise taking the medication on an empty stomach, separating it from meals by two to three hours. The granules must be dissolved completely in a glass of water and consumed right away. Official instructions do not authorize mixing the granules with other liquids, such as juice or milk.


Q: Can Монурал be taken by men, or is it only for women?

Regulatory documents state the medicine is primarily indicated for the treatment of uncomplicated UTIs in women and adolescent girls. However, it is also approved for use in men for the prevention of infection when undergoing a transrectal prostate biopsy.


Q: What happens if I experience side effects after taking the medicine?

Patients are advised to seek immediate medical help for signs of a serious allergic reaction, such as hives, swelling of the face, or difficulty breathing. For persistent or worsening common side effects like headache or nausea, official patient instructions suggest checking with a healthcare professional.


Q: How does Монурал compare to other common UTI treatments?

Clinical studies show that the treatment outcomes with this medicine were generally similar to the results reported for other antibiotics commonly used for uncomplicated UTIs. Studies indicate the outcomes are similar, and its unique structure helps to minimize the potential for cross-resistance with other classes of antibiotics.


Q: Why do some people say Монурал is better than other antibiotics?

Clinical studies show similar outcomes compared to other antibiotics for uncomplicated UTIs. Official documents highlight the convenient single-dose administration and unique chemical structure as differentiating factors.


Q: Is the medication Монурал available in different strengths or forms?

The oral product intended for uncomplicated UTIs is supplied exclusively as a 3 g granule formulation for oral solution. However, other fosfomycin salt formulations and strengths, including intravenous preparations, are available globally for use in different indications.


Q: Is Монурал safe to use for a recurrent infection?

Official labeling advises selecting other therapeutic agents if persistence or reappearance of bacteriuria (bacteria in the urine) occurs after treatment. Regulatory labeling advises selecting other therapeutic agents if the infection reoccurs.


Q: Do studies support the use of Монурал in preventing recurrent UTIs?

Research evidence supports its use for the prevention of infection (prophylaxis) following specific medical procedures, such as prostate biopsy. However, studies had limited follow-up duration (often le 30 days post-treatment) and do not establish long-term effects for general recurrent UTI prevention.


Q: Is it true that Монурал is not used in the United States?

The active ingredient, fosfomycin tromethamine (available under brand names like Monurol), is approved for use by the U.S. Food and Drug Administration (FDA) for the treatment of uncomplicated urinary tract infections.


Q: Does Монурал treat the pain of a UTI, or just the bacteria?

The regulatory intent of the drug is to eliminate the bacteria that are causing the infection. By eliminating the underlying cause, the medicine facilitates the resolution of symptoms, including discomfort, which is monitored in clinical studies.


Q: Is it okay to mix Монурал with juice instead of water?

Official administration instructions specify that the entire contents of the sachet must be fully dissolved in a glass of water and consumed immediately. These regulatory directions do not authorize or confirm the safety of mixing the granules with other liquids, such as juice.


Q: Can Монурал cause changes in appetite?

Official documents note that a change in appetite, specifically loss of appetite, has been reported as an adverse reaction. This side effect has been noted with an incidence that is considered rare in some clinical reports.


Q: Is it safe to drink alcohol in small amounts while taking Монурал?

Due to the risk of common side effects like dizziness, patient information advises caution with alcoholic beverages. Official guidance advises patients to consult with a healthcare professional regarding alcohol consumption.


Q: Do any official sources mention Монурал's effect on liver function?

Official documents, including adverse reaction reports, note that rare and usually temporary increases in liver enzymes have been observed in studies. Rare cases of clinically apparent liver injury have also been reported.


Q: Are there any known interactions between Монурал and herbal supplements?

Official patient information states that all medications, including any over-the-counter products, herbal products, and other supplements, should be discussed with a healthcare professional before taking the medicine.


Q: Does Монурал cause drowsiness or affect driving ability?

The medication commonly causes side effects such as dizziness. Official patient safety information advises caution regarding activities requiring alertness, such as driving or operating machinery, until you are certain how the medicine affects you.


Q: How long after taking Монурал should symptoms start to improve?

Clinical information indicates that symptom improvement may begin within 24 to 48 hours after taking the dose. Although the drug acts rapidly to reach the site of infection, the timeline for the relief of clinical symptoms is usually measured in days.


Q: Why do some instructions recommend taking Монурал before bedtime?

Administration before bedtime is often recommended after the patient has emptied their bladder. This timing is intended to help maximize the concentration of the drug within the bladder overnight, which prolongs its exposure to the infection site.


Q: Is there a risk of antibiotic resistance with Монурал?

While the drug's unique mechanism helps minimize cross-resistance with other classes of antibiotics, resistance to fosfomycin itself can occur. Official labeling includes specific criteria used by labs to determine if a bacteria strain is resistant to the drug.


Q: Are there any long-term side effects associated with Монурал?

Official research evidence notes that long-term effects are not fully established due to limited follow-up duration (often le 30 days) in the studies. However, some severe complications, such as C. difficile-associated diarrhea, have been reported to occur two months or more after administration.


Q: What if the infection symptoms do not improve after using Монурал?

Patients are advised to check with a doctor or healthcare professional if their symptoms do not improve within two or three days after taking the dose, or if their symptoms become worse during this period.


Q: Does Монурал treat yeast infections, or only bacterial infections?

This medicine is classified as a bactericidal antibiotic, meaning it is intended only to eliminate susceptible bacteria. It does not treat yeast infections, and vulvovaginitis is listed as a common side effect, which may suggest the drug can sometimes disrupt the normal balance of flora.


Q: Is Монурал used to treat asymptomatic bacteriuria?

The general indication is restricted to treating only uncomplicated (symptomatic) lower urinary tract infections. However, its use is conditionally permitted during pregnancy, which is a population where treatment for asymptomatic bacteriuria is often indicated.


Q: Do people with diabetes need to take any special precautions with Монурал?

Official patient information states caution is warranted for individuals with diabetes. This is because the granule formulation contains sucrose (sugar) and other inactive ingredients that may need to be factored into dietary management.


Q: What kind of bacteria is Монурал effective against?

Regulatory documents indicate the drug has been shown to be effective against most strains of specific microorganisms associated with uncomplicated UTIs. These include Enterococcus faecalis and Escherichia coli.

How should Монурал be stored and disposed of?

How to Store and Dispose of Monurol (Fosfomycin Trometamol)

The storage of Monurol granules must strictly follow regulatory conditions to maintain stability. The product must be stored at Controlled Room Temperature, which is 25 C (77 F), with excursions allowed between 15 C and 30 C (59 F and 86 F). The medicine must be kept in its original packet/container and protected from moisture; it should not be frozen.

Child Safety and Disposal

Monurol must be stored out of the sight and reach of children.

For disposal, do not throw unused or expired medicine in household trash or flush it down the toilet into wastewater. The proper procedure requires returning the product to a pharmacy or local waste disposal company for disposal according to local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Монурал found in:

A-Z Index: